DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hereditary spastic paraplegia 7 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary spastic paraplegia 7 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary spastic paraplegia 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mutY DNA glycosylase (MUTYH) — MUTYH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sf4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8FAY · 1.91 Å · ligand IRON/SULFUR CLUSTER (SF4). Experimental structure, not a prediction.
What the evidence adds up to
No drug treatment is tested or reported in any of these abstracts. The 2017 review states that balance impairments are common and debilitating in hereditary spastic paraplegia, causing falls, and that multidisciplinary treatment tailored to identified mechanisms can improve balance and prevent some falls, but the recommendations are based on practice-based evidence and clinical experience, not on controlled trials. The 1988 paper describes six families with 26 affected members, all children with slowly progressive paraplegia and delayed motor milestones, and notes that treatment when necessary consisted of tendon lengthenings, not drugs. The 2015 paper reports that in Caucasian populations heterozygous Spastin mutations (SPG4) account for the majority of patients, with onset typically in the third or fourth decade, and that childhood onset is more common in SPG3a or complicated forms such as SPG11. The 2005 paper describes HSP with thin corpus callosum and childhood onset in two patients, but gives no treatment data. The 2006 paper reports a novel phenotype of complicated autosomal recessive HSP caused by a new homozygous SPG7 mutation in a Turkish family, noting that SPG7 mutations account for less than 5% of autosomal recessive HSP families, but again no drug is mentioned.
Across these five abstracts, no pharmacological intervention for hereditary spastic paraplegia 7 or any HSP subtype is evaluated. The only interventions described are non-drug: tendon lengthening surgery in the 1988 series and multidisciplinary balance management in the 2017 review. No response rates, survival figures, or drug-related outcomes are available because no drug trial data are presented. The genetic heterogeneity of HSP is emphasised, with SPG7 mutations being rare, but no therapy directed at the underlying mutation is discussed.
What is missing is any controlled trial of a drug for HSP7, any patient stratification by mutation type in a treatment study, and any funding for such a trial. Without these, the management of balance impairments and falls remains empirical, based on clinical experience rather than evidence from randomised studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Rehabilitation Medicine · 2017 · 22 citations · open access
Pathophysiology, diagnostic work-up and management of balance impairments and falls in patients with hereditary spastic paraplegia
AbstractINTRODUCTION: Balance impairments are common in patients with hereditary spastic paraplegia and are among the most debilitating symptoms, as they frequently result in falls and fall-related injuries. Several features of hereditary spastic paraplegia contribute to balance impairments and multiple treatment options exist. However, an overview of these underlying mechanisms and their treatment is currently lacking. METHODS: This paper reviews the pathophysiology, diagnostic workup, and management of balance impairments in hereditary spastic paraplegia. Recommendations are based on scientific evidence, when available, and otherwise reflect practice-based evidence supported by clinical experience. CONCLUSION: Through diligent history-taking and clinical examination, followed by multidisciplinary treatment tailored to the identified underlying mechanisms, balance capacities can be improved in patients with hereditary spastic paraplegia and at least a proportion of falls can be prevented.
Journal of Pediatric Orthopaedics · 1988 · 11 citations
Hereditary Spastic Paraplegia
AbstractHereditary spastic paraplegia is a genetically transmitted disease that is usually autosomal dominant. Characterized by a slow progression of spastic paraparesis, it is frequently misdiagnosed as cerebral palsy. Our experience consists of six families with a total of 26 affected members. All initial referrals were children with a slowly progressive paraplegia. Each child was noted to have slightly delayed motor milestones, normal intellect, and no history of perinatal cerebral event. Each child was treated when necessary with appropriate tendon lengthenings. Recognition is the key to management. A careful patient and family history will reveal the hereditary nature of the disease and help develop treatment plans.
Mutation Spectrum and Infantile Manifestation in Hereditary Spastic Paraplegia
AbstractAims: Hereditary spastic paraplegia (HSP) is genetically heterogeneous and clinically characterized by gait impairment because of weakness and spasticity of the lower limbs. In Caucasian populations, heterozygous Spastin mutations account for the majority of patients (SPG4) with predominant clinical manifestation within the third or fourth decade of life. A clinical manifestation during childhood is well known, but more common in less frequent forms such as SPG3a or complicated HSP, for example, SPG11.
Hereditary spastic paraplegia with thin corpus callosum – childhood onset in two patients
AbstractBackground: The hereditary spastic paraplegias (HSPs) are a group of rare disorders with the predominant clinical feature of spastic gait. They are subdivided into pure and complicated forms according to whether the disorder is associated with other neurologic abnormalities. Autosomal dominant, recessive and X-linked forms of HSP have been defined.
Complicated autosomal recessive hereditary spastic paraplegia with vertical eye movement paresis (Parinaud's syndrome): a novel phenotype caused by a new homozygous SPG7 gene mutation
AbstractAims: Hereditary spastic paraplegia (HSP) is a clinically and gentically heterogenous neurodegenerative disorder. Clinically an uncomplicated and a complicated form can be distinguished. The uncomplicated form is characterised by slow progressive spastic paraparesis and disturbation of micturition. For the complicated forms a huge number of additional symptoms have been reported. So far thirty-one different genetic loci (SPG1–31) are known. SPG7 encodes the protein paraplegin, which is a mitochondrial metalloprotease. Mutations of SPG7 account for less than 5% of autosomal recessive hereditary spastic paraplegia (ARHSP) families. We report a novel phenotype of complicated ARHSP caused by a new homozygous SPG7 mutation in a family of Turkish decent.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
